Tepotinib (Tuodekang) usage and dosage and daily medication precautions

Tepotinib is a selective METtyrosine kinase inhibitor, mainly used to treat patients with METexon14 skipping mutation-positive non-small cell lung cancer (NSCLC). The drug exerts anti-tumor effects by inhibiting the MET signaling pathway and blocking tumor cell proliferation and migration. As a targeted therapy drug, tepotinib has strict requirements on dosage and usage in clinical use to ensure drug efficacy and safety.

For standard use, tepotinib is usually taken as an oral capsule once daily. The recommended dose is 450mg. Take three 150mg capsules orally each time. Swallow them whole and do not chew or break them. A fixed time should be chosen when taking the medicine. It is usually recommended to take it every morning or at a time that the patient is accustomed to, in order to keep the blood concentration of the medicine stable and ensure the continued effect of the medicine. If the patient misses a dose, he should take it as soon as possible. However, if the next dose is close, skip the missed dose and do not double the dose at once to avoid increasing the risk of adverse reactions.

In terms of medication precautions, Tepotinib can be taken on an empty stomach or with food. However, if gastrointestinal discomfort occurs, it can be taken after a meal to reduce side effects. During daily medication, patients should avoid concurrent use with strong acid-suppressing drugs (such as proton pump inhibitors) or certain antifungal drugs to avoid affecting drug absorption and efficacy. At the same time, liver function, hematological indicators and electrocardiogram need to be monitored regularly during treatment in order to detect and deal with potential adverse reactions in a timely manner. Common side effects include edema, mild to moderate nausea, diarrhea, and muscle pain, which in most cases can be alleviated through lifestyle intervention or symptomatic treatment.

In individualized medication management, doctors will adjust the dosage according to the patient's age, liver and kidney function, and concomitant medications. For example, doses may need to be reduced in patients with moderate hepatic impairment, and use with caution or contraindication in patients with severe hepatic impairment. In addition, during tepotinib treatment, attention should be paid to the long-term continuity of the drug, and arbitrary discontinuation of the drug should be avoided to avoid affecting the efficacy. Patients and their families should strictly follow medical instructions, combine regular imaging evaluations and blood tests, and scientifically manage daily medication to maximize treatment effects while ensuring medication safety.

In general, the daily dosage and precautions of tepotinib are crucial to the clinical efficacy. Standardized medication use, regular monitoring and individualized adjustments are the keys to ensuring patients get the best results and the lowest side effects. By strictly abiding by medication rules, scientifically managing side effects and regular follow-up, tepotinib can achieve effective tumor control in patients with non-small cell lung cancer positive for exon 14 skipping mutations, providing a reliable solution for clinical treatment.

Reference link:https://www.drugs.com